Clinical Trial Update: Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial updates are evaluating combinations of Anetumab Ravtansine with Nivolumab, or with Nivolumab plus Ipilimumab, and with Gemcitabine and Ni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Anetumab Ravtansine (anetumab ravtansine)
• Gemcitabine (Gemcitabine)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 1 | Status: ACTIVE_NOT_RECRUITING